Clinical Trial Update: Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia [Phase 3]

View source ↗

Summary

This Phase 3 trial compared anagrelide to hydroxyurea in patients with essential thrombocythemia to assess efficacy and tolerability; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• ANAGRELIDE (Anagrelide)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: AOP Orphan Pharmaceuticals AG | Conditions: Essential Thrombocythaemia | Phase 3 | Status: COMPLETED